article Open AccessTop 1% cited
Apixaban, an oral, direct factor <scp>X</scp>a inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects
British Journal of Clinical Pharmacology · 2012 · Vol. 75(2) · pp. 476–487
Charles Frost✉(Bristol-Myers Squibb (United States))Jessie J. Wang(Bristol-Myers Squibb (United States))Sunil Nepal(Bristol-Myers Squibb (United States))Alan Schuster(Bristol-Myers Squibb (United States))Yu Chen Barrett(Bristol-Myers Squibb (United States))Rogelio Mosqueda‐Garcia(Bristol-Myers Squibb (United States))Richard A. Reeves(Bristol-Myers Squibb (United States))Frank LaCreta(Bristol-Myers Squibb (United States))
Abstract
Single doses of apixaban were well tolerated with a predictable pharmacokinetic/pharmacodynamic profile and a half-life of approximately 12 h. Apixaban can be administered with or without food.
Atrial Fibrillation Management and OutcomesCardiac electrophysiology and arrhythmiasPharmacovigilance and Adverse Drug ReactionsApixabanPharmacokineticsPharmacodynamicsCrossover studyPartial thromboplastin timePharmacologyMedicinePlaceboProthrombin timeAnesthesia
MeSH terms
Administration, OralAdultDouble-Blind MethodFastingFibrinolytic AgentsHalf-LifeHumansMalePyrazolesPyridonesTime FactorsFood-Drug InteractionsCross-Over StudiesArea Under CurveYoung Adult
Funding
- Bristol-Myers Squibb
- Pfizer
Citations
358
FWCI
24.48
field-weighted impact
References
38
Percentile
100%
vs. same field & year
Citations per year
References
Muscular exercise can cause highly pathological liver function tests in healthy men
British Journal of Clinical Pharmacology · 2007 · 346 citations
Pharmacology and Management of the Vitamin K Antagonists
CHEST Journal · 2008 · 2,096 citations
Apixaban versus Warfarin in Patients with Atrial Fibrillation
New England Journal of Medicine · 2011 · 8,827 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.